Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

NCT06891755 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?

Conditions Studied

Interventions

  • DEVICE Apreo BREATHE Airway Scaffold
  • OTHER Optimal Medical Management (OMM)

Study Locations (19)

Pennsylvania

  • Clinical Research Associates of Central Pennsylvania — DuBois
  • Temple University — Philadelphia
  • University of Pittsburgh Medical Center — Pittsburgh

Florida

  • Mayo Clinic — Jacksonville
  • Orlando Health — Orlando

Illinois

  • University of Chicago — Chicago
  • OSF St Francis Medical Center — Peoria

Ohio

  • Cleveland Clinic Foundation — Cleveland
  • The Ohio State University — Columbus

Other

  • University Medical Center Groningen — Groningen
  • Royal Brompton Hospital — London

Alabama

  • University of Alabama at Birmingham — Birmingham

Arizona

  • Banner Health — Gilbert

California

  • University of California at Davis — Sacramento

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-07-15
Est. Completion 2029-12-31
Phase NA

Sponsor

Apreo Health

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06891755

The ClinicalTrials.gov registry entry for NCT06891755 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apreo Health, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with COPD appearing as the primary indexed condition, and to 2 interventions — of which Apreo BREATHE Airway Scaffold is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06891755 reports 19 study locations spanning 13 distinct geographic areas — top geographies include Pennsylvania, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06891755 about?

NCT06891755 is a clinical study titled "Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3". The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATH...

What is the current status of trial NCT06891755?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2025-07-15. Estimated completion is 2029-12-31.

What conditions does trial NCT06891755 study?

This clinical trial studies the following conditions: COPD, Emphysema. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06891755?

The interventions under investigation include: Apreo BREATHE Airway Scaffold (DEVICE), Optimal Medical Management (OMM) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06891755?

This trial is sponsored by Apreo Health, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06891755 being conducted?

This trial has 19 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial